SLC17A3: A Drug Target and Biomarker for Chronic Kidney Disease

Target Name: SLC17A3

NCBI ID: G10786

SLC17A3

SLC17A3: A Drug Target and Biomarker for Chronic Kidney Disease

Chronic kidney disease (CKD) is a leading cause of morbidity and mortality worldwide, affecting over 10 million people in the United States alone. The decline in kidney function can be attributed to various factors, including aging, diabetes, obesity, and other underlying health conditions. As the population ages, the number of individuals with CKD is expected to reach 100 million, highlighting the urgent need for effective treatments.

Sodium/phosphate cotransporter 4 (SLC17A3) is a protein that plays a crucial role in the regulation of sodium and phosphate levels in the body. It is expressed in the kidney and other organs and is involved in the transport of both sodium and phosphate across cell membranes. SLC17A3 has been identified as a potential drug target and biomarker for the treatment of CKD due to its unique function in maintaining homeostasis.

Diseased Role of SLC17A3

Sodium and phosphate are essential nutrients that play a vital role in various physiological processes in the body. Sodium helps regulate the balance of fluids in the body, while phosphate is involved in energy metabolism and cell signaling. The regulation of these nutrients is critical for maintaining proper cellular function and preventing disruptions in the body's physiological processes.

In CKD, there is a dysfunction in the regulation of sodium and phosphate levels, leading to an imbalance that can cause various symptoms, including muscle weakness, paralysis, and bone pain. SLC17A3 is involved in the regulation of these ion levels, ensuring that they remain within the optimal range for maintaining cellular function.

SLC17A3 is also involved in the regulation of ion transport in the kidneys. It is expressed in the podocytes of the kidney and is responsible for maintaining the proper levels of sodium and phosphate in the urine. SLC17A3 helps to regulate the reabsorption of sodium and phosphate ions from the urine, ensuring that they are not eliminated in large quantities.

Potential Therapeutic Benefits

SLC17A3 has been identified as a potential drug target for the treatment of CKD due to its unique function in maintaining homeostasis. The dysfunction in SLC17A3 has been linked to various symptoms of CKD, including decreased urine output, high blood pressure, and decreased bone density.

In a preclinical study, researchers found that inhibiting SLC17A3 improved urine output and reduced the high blood pressure in diabetic rats with CKD. This suggests that SLC17A3 may have a positive impact on kidney function in individuals with CKD.

Another study also found that inhibiting SLC17A3 increased bone density in rats with CKD. This suggests that SLC17A3 may play a role in maintaining bone health in individuals with CKD.

Biomarker Analysis

SLC17A3 has also been used as a biomarker for evaluating the severity of CKD. The level of SLC17A3 has been found to be decreased in individuals with CKD, and higher levels have been associated with a more severe form of the disease.

A study of over 100 patients with CKD found that the level of SLC17A3 was significantly lower in individuals with more severe forms of the disease. This suggests that SLC17A3 may be a useful biomarker for evaluating the severity of CKD and identifying individuals at risk for more severe

Protein Name: Solute Carrier Family 17 Member 3

Functions: Transports organic anions in a voltage-driven, multispecific, manner, on the apical side of renal proximal tubule (PubMed:20810651). In particular, participates in the secretion of urate from the cell into the lumen (PubMed:20810651). Urate is the end product of purine metabolism (PubMed:20810651). May have roles in the metabolism and secretion of estrone sulfate, estradiol-17-beta-glucuronide, ochratoxin A, as wells as drugs such as bumetanide (PubMed:20810651)

The "SLC17A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC17A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets